politics

Eli Lilly's Foundayo Receives Approval in the U.K. for Weight-Loss Treatment

11 Ağustos 2026CNBC

Eli Lilly's weight-loss pill, Foundayo, has received approval in the U.K., marking a significant step in its competition with Novo Nordisk's Wegovy. This expansion beyond the U.S.
market highlights Lilly's commitment to addressing obesity on a global scale. The approval may lead to increased market share for Lilly as it positions itself against established competitors in the weight-loss medication sector.
The weight-loss medication market has become increasingly competitive, with major players like Eli Lilly and Novo Nordisk vying for dominance. has been the primary market for these drugs, but expanding into the U.K.
The approval of Foundayo in the U.K. signifies a strategic move by Eli Lilly to not only capture a share of the growing weight-loss market but also to challenge the dominance of Wegovy.

NewsAI özeti

This article is for informational purposes only and does not constitute medical advice.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.